PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy
to determine MTD and RP2D and Phase II is open label randomized four parallel arms to access
anti tumour efficacy in mTNBC